Allan Cass, MD
Radiation Oncology · Crown Point, INNPI 1609889203
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $474 of the $705 with a category attached, or 67.2%. 16 manufacturers reported payments, led by Legend Biotech USA Inc. at 36.2% of the total. That places this record below the midpoint for radiation oncology clinicians in IN, where the typical reported total is $556.
Across 40 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Legend Biotech USA Inc.$255
- AstraZeneca$94
- Novartis$50
- Pfizer$48
- Verastem, Inc.$39
- Lilly USA, LLC$36
- plus $183 from 10 others
What the payments were for
- Food & beverage$47467%
- Education$23133%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Legend Biotech USA Inc. | 10 | $255 |
| AstraZeneca | 6 | $94 |
| Novartis | 3 | $50 |
| Pfizer | 4 | $48 |
| Verastem, Inc. | 3 | $39 |
| Lilly USA, LLC | 2 | $36 |
| Johnson & Johnson | 2 | $31 |
| Sanofi | 2 | $26 |
| Amgen | 1 | $21 |
| Taiho Oncology, Inc. | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Stemline Therapeutics Inc. | 1 | $16 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $11 |
How this compares
$705 in reported general payments places this provider in the 50th percentile of 116 radiation oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 11 | $101 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Crown Point
- Brian ChangFort Wayne$13K
- Michael EatonIndianapolis$11K
- William PorterMadison$8K
- Binh TranMishawaka$7K
- Gordon WatsonIndianapolis$6K
- John CoxIndianapolis$5K
- Houman VaghefiGoshen$5K
- Peter GarrettIndianapolis$5K
- Garrett JensenIndianapolis$4K
- Douglas DebenhamNewburgh$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.